Skip to main content

Advertisement

Table 2 Randomized controlled trials included in the review (n = 4)

From: Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)

Study ID Funding Country & Setting Intervention Comparison Weeks (sessions) Total randomised Mean age of sample % female in sample Diagnostics & baseline screening Primary measures Secondary measures Drop-outs Lost to follow-up
Medication
Aliyev and Aliyev 2011 None Azerbaijan outpatients (single centre) Lamotrigine (dose: 25–300 mg/day) Placebo 12 80 37.7 0 CDS CDS Improvement 15 -
Sierra et al. 2003 None UK outpatients (single centre) Lamotrigine (dose: 25–250 mg/day) Placebo 12 14 35.2   DSM-IV PSE DES 5 -
PSE CDS BDI
CDS   
Simeon et al. 2004 NIMH grant USA outpatients (single centre) Fluoxetine (dose: 10–60 mg/day) (provided by Eli Lilly) Placebo 10 54 36 39 SCID-D CGI-I HRSA 13 -
Semi-structured clinical interview DES-DP HRSD
DSS LSAS
YBOCS
Panic attacks
Psychotherapy
Schoenberg et al. 2012 Medical Research Council UK outpatient (single centre) Electro-dermal biofeedback (8 sessions) Sham electro-dermal biofeedback 4 (8) 32 35 25 SCID-D CDS - 2 -
DES
  BAI
  Pilkington Pilozzo Charitable Trust          BDI